An Updated Review on the Chemistry, Biological Characteristics and Ana-lytical Techniques of Dapagliflozin

IF 0.9 Q4 CHEMISTRY, PHYSICAL

Current Organocatalysis Pub Date : 2023-08-09 DOI:10.2174/2213337210666230627153351

Ujwala Chaudhari, J. Sahu, P. Dande

{"title":"An Updated Review on the Chemistry, Biological Characteristics and Ana-lytical Techniques of Dapagliflozin","authors":"Ujwala Chaudhari, J. Sahu, P. Dande","doi":"10.2174/2213337210666230627153351","DOIUrl":null,"url":null,"abstract":"\n\nGlobally, type 2 diabetes mellitus (T2DM) prevalence is increasing. A patient must have lifetime therapy for diabetes to manage it and prevent any complications. There are many different medications that can be used to treat Type 2 diabetes. Still, almost all of them concentrate on the declining insulin sensitivity and secretion that are associated with the onset of the illness.\n\n\n\nThere is growing interest in the development of innovative anti-diabetic medications that are not insulin-reliant because treatments with such insulin-dependent mechanisms of action usually lose their effectiveness over time. One such technique is the inhibition of renal glucose reuptake.\n\n\n\nDapagliflozin, the first line of selective sodium-glucose cotransporter 2 inhibitors that re-duce renal glucose reabsorption, is currently being developed as a therapy for Type 2 diabetes. Numerous analytical techniques have been developed for its detection, measurement, and regular quality control procedures.\n\n\n\nThis review deliberates a thorough discussion on the chemistry of Dapagliflozin, all of its pharmacological actions with analytical and bioanalytical analyses, and more information on the clinical trials.\n","PeriodicalId":10945,"journal":{"name":"Current Organocatalysis","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Organocatalysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2213337210666230627153351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Globally, type 2 diabetes mellitus (T2DM) prevalence is increasing. A patient must have lifetime therapy for diabetes to manage it and prevent any complications. There are many different medications that can be used to treat Type 2 diabetes. Still, almost all of them concentrate on the declining insulin sensitivity and secretion that are associated with the onset of the illness. There is growing interest in the development of innovative anti-diabetic medications that are not insulin-reliant because treatments with such insulin-dependent mechanisms of action usually lose their effectiveness over time. One such technique is the inhibition of renal glucose reuptake. Dapagliflozin, the first line of selective sodium-glucose cotransporter 2 inhibitors that re-duce renal glucose reabsorption, is currently being developed as a therapy for Type 2 diabetes. Numerous analytical techniques have been developed for its detection, measurement, and regular quality control procedures. This review deliberates a thorough discussion on the chemistry of Dapagliflozin, all of its pharmacological actions with analytical and bioanalytical analyses, and more information on the clinical trials.

查看原文本刊更多论文

达格列嗪的化学、生物学特性及分析技术研究进展

在全球范围内，2型糖尿病(T2DM)的患病率正在上升。患者必须终生治疗糖尿病以控制病情并预防并发症。有许多不同的药物可用于治疗2型糖尿病。尽管如此，几乎所有的研究都集中在与疾病发病有关的胰岛素敏感性和分泌下降上。人们对开发不依赖胰岛素的创新抗糖尿病药物越来越感兴趣，因为使用这种依赖胰岛素的作用机制的治疗通常会随着时间的推移而失去有效性。其中一项技术是抑制肾脏葡萄糖再摄取。达格列净(Dapagliflozin)是一线选择性钠-葡萄糖共转运蛋白2抑制剂，可减少肾脏葡萄糖重吸收，目前正被开发用于治疗2型糖尿病。许多分析技术已经开发出来用于其检测、测量和常规质量控制程序。本文对达格列净的化学性质、药理作用、分析和生物分析进行了全面的讨论，并对临床试验进行了详细的介绍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Organocatalysis CHEMISTRY, PHYSICAL-

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： Current Organocatalysis is an international peer-reviewed journal that publishes significant research in all areas of organocatalysis. The journal covers organo homogeneous/heterogeneous catalysis, innovative mechanistic studies and kinetics of organocatalytic processes focusing on practical, theoretical and computational aspects. It also includes potential applications of organocatalysts in the fields of drug discovery, synthesis of novel molecules, synthetic method development, green chemistry and chemoenzymatic reactions. This journal also accepts papers on methods, reagents, and mechanism of a synthetic process and technology pertaining to chemistry. Moreover, this journal features full-length/mini review articles within organocatalysis and synthetic chemistry. It is the premier source of organocatalysis and synthetic methods related information for chemists, biologists and engineers pursuing research in industry and academia.